Monday, February 28, 2022

New Information on Treatment of Moderate to Severe Crohn’s Disease

AbbVie today announced that the U.S. Food and Drug Administration (FDA) has extended its review period for SKYRIZI® (risankizumab-rzaa) for the treatment of moderate to severe Crohn’s disease in patients 16 years and older. The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date by three months to review additional data submitted by AbbVie, including information about the on-body injector, for this new proposed indication. Currently approved indications for SKYRIZI are not affected by this extension. SKYRIZI […] - eTurboNews | Trends | Travel News Online
http://dlvr.it/SKrYqW

No comments:

Post a Comment